Department of Hepatology, The Third Central Clinical College of Tianjin Medical University, Tianjin, China.
Department of Hepatology, The Third Central Hospital of Tianjin, Tianjin, China.
J Clin Lab Anal. 2020 Jun;34(6):e23247. doi: 10.1002/jcla.23247. Epub 2020 Feb 26.
Spontaneous bacterial peritonitis (SBP) is one of the most critical complications of decompensated liver cirrhosis. This study aimed to assess whether ascitic neutrophil gelatinase-associated lipocalin (NGAL), a reliable inflammation biomarker, can be used to detect SBP in decompensated cirrhosis patients and to predict mortality from decompensated cirrhosis-related SBP.
This study included 204 hospitalized patients with ascites of decompensated liver cirrhosis and follow-up of 28 days. We measured ascitic NGAL levels by the latex-enhanced immunoturbidimetric method. Simultaneously, we observed the patterns of ascitic NGAL levels in the SBP group after 7 days of anti-infection treatment with third-generation cephalosporins.
The ascitic NGAL levels significantly increased in the SBP group compared with that in the non-SBP group, 111(83.9, 178) ng/mL vs 48(35.4, 63) ng/mL, P < .001. Likewise, the ascitic NGAL levels of SBP were higher than non-SBP with or without renal dysfunction. There was a positive relationship between ascitic NGAL and ascitic polymorphonuclear (PMN) leukocyte and a negative relationship between ascitic NGAL and ascitic albumin in the SBP group. An ascitic NGAL cutoff of 108.95 ng/mL was used for predicting a poor prognosis for SBP patients. Ascitic NGAL and the model for end-stage liver disease score were independent risk factors in decompensated liver cirrhosis patients with SBP through multivariate Cox regression. A dynamic trend of ascitic NGAL in SBP patients was consistent with the clinical prognosis.
Ascitic NGAL may not only be a biomarker for monitoring SBP but also a predictor for more severe outcomes in decompensated cirrhosis-related SBP.
自发性细菌性腹膜炎(SBP)是失代偿性肝硬化最严重的并发症之一。本研究旨在评估腹水中性粒细胞明胶酶相关脂质运载蛋白(NGAL)是否可作为一种可靠的炎症标志物,用于检测失代偿性肝硬化患者中的 SBP,并预测与失代偿性肝硬化相关的 SBP 导致的死亡率。
本研究纳入了 204 例患有失代偿性肝硬化腹水且随访 28 天的住院患者。采用胶乳增强免疫比浊法测定腹水 NGAL 水平。同时,观察了第三代头孢菌素抗感染治疗 7 天后 SBP 组腹水 NGAL 水平的变化模式。
与非 SBP 组相比,SBP 组腹水 NGAL 水平明显升高,分别为 111(83.9,178)ng/mL 和 48(35.4,63)ng/mL,P<0.001。同样,伴有或不伴有肾功能障碍的 SBP 患者的腹水 NGAL 水平也高于非 SBP 患者。在 SBP 组中,腹水 NGAL 与腹水多形核(PMN)白细胞呈正相关,与腹水白蛋白呈负相关。腹水 NGAL 截断值为 108.95ng/mL 时,可预测 SBP 患者的预后不良。腹水 NGAL 和终末期肝病模型评分是通过多变量 Cox 回归分析确定的失代偿性肝硬化伴 SBP 患者的独立危险因素。SBP 患者腹水 NGAL 的动态趋势与临床预后一致。
腹水 NGAL 不仅可以作为监测 SBP 的生物标志物,还可以预测与失代偿性肝硬化相关的 SBP 患者更严重的结局。